Raffit Hassan, M.D.
Dr. Hassan has played a pivotal role in validating the tumor differentiation antigen mesothelin as a target for cancer therapy and development of mesothelin targeted immunotherapy. This work has laid the foundation for several mesothelin directed agents that he is evaluating in the clinic for treatment of mesothelioma, lung and pancreatic cancer. His clinical trials using an anti-mesothelin immunotoxin has shown major tumor responses in patients with mesothelioma. Ongoing efforts are directed to exploiting this approach for treatment of lung and pancreatic cancer.
1) mesothelioma, 2) mesothelin, 3) immunotoxins, 4) immunotherapy, 5) lung cancer,
6) pancreatic cancer
Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant MesotheliomaOpen - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-059Investigator Raffit Hassan, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Yvonne Mallory 240.760.6116
Dr. Hassan's research interest is focused on developing targeted immunotherapy, especially immunotoxins, for patients with malignant mesothelioma and other solid tumors. While working as a postdoctoral fellow in the laboratory of Dr. Ira Pastan, Dr. Hassan did pioneering preclinical work on the tumor differentiation antigen mesothelin as a target for cancer therapy and he has played a key role in bringing mesothelin-directed therapies to the clinic.
A major focus of the Hassan laboratory is developing mesothelin-targeted agents for treating cancer. These include an anti-mesothelin immunotoxin (SS1P), a chimeric monoclonal antibody to mesothelin (Amatuximab), an anti-mesothelin antibody drug conjugate (BAY 94-9343) and a mesothelin vaccine (CRS-207).
His initial pre-clinical studies and early phase clinical trials of the immunotoxin SS1P validated mesothelin as a therapeutic target for cancer therapy. His work is now focused on increasing the efficacy of SS1P in patients. The two approaches his laboratory is studying include combining SS1P with chemotherapy and decreasing the immunogenicity of immunotoxins. His group has recently shown major and durable tumor responses in patients with treatment refractory mesothelioma by combining SS1P with immunosupression. This work opens up the field of immunotoxin therapy for solid tumors and ongoing studies will elevate this approach for treatment of common cancers, including lung adenocarcinoma. In addition, Dr. Hassan and his collaborators will continue to develop less immunogenic immunotoxins for treatment of cancer.
His laboratory studies include development of mesothelioma patient-derived xenografts that mimic the molecular characteristics of patient tumors and are valuable for preclinical studies of mesothelin-directed agents. In addition, his laboratory studies the role of mesothelin in different tumors, the tumor immune environment of human meosthelioma and changes following treatment with immunotoxin therapy.
Selected Key Publications
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.Sci Transl Med. 12 (550): 2020. Full-Text Article [ Journal Article ]
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.Cancer. 126 (22): 4936-4947, 2020. Full-Text Article [ Journal Article ]
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.J Clin Oncol. 38 (16): 1824-1835, 2020. Full-Text Article [ Journal Article ]
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.Proc Natl Acad Sci USA. 116 (18): 9008-9013, 2019. Full-Text Article [ Journal Article ]
- Clin Cancer Res. 24 (12): 2859-2872, 2018. Full-Text Article [ Journal Article ]
Dr. Raffit Hassan is a medical oncologist and senior investigator at NCI. He received his medical degree from the University of Kashmir, India in 1988 and did his internship and residency training in internal medicine at Sisters Hospital, University of Buffalo and subsequently completed his medical oncology fellowship at the NCI. After finishing his fellowship training he joined the medical faculty at the University of Oklahoma in 1998. He returned to NCI as a tenure track investigator in 2002 and received tenure in 2008. Dr. Hassan is a recipient of the ASCO Career Development Award, the NIH Patient Oriented Research Career Development Award and the Pioneer Award from the Mesothelioma Foundation.
|Maria Garcia Agra R.N.||Clinical Research Nurse (Contr)|
|Romi Biswas Ph.D.||Research Fellow|
|Gideon Blumenthal M.D.||Clinical Collaborator|
|Qun Jiang Ph.D.||Staff Scientist|
|Mana Kamana Khanal Ph.D.||Postdoctoral Fellow (Visiting)|
|Chul Kim M.D.||Clinical Fellow|
|Firouzeh Korangy Ph.D.||Scientist (Contr)|
|Idrees Mian M.D.||Clinical Fellow|
|Vikram Misra Ph.D.||Bioinformatics Scientist (Contr.)|
|Manjistha Sengupta Ph.D.||Clinical Trials Specialist (Contr.)|
|Chaido Stathopoulou Ph.D.||Postdoctoral Fellow (Visiting)|
|Sakshi Tomar Ph.D.||Postdoctoral Fellow (Visiting)|